A compound comprising ##STR00001## or a pharmaceutically acceptable salt or a prodrug thereof, wherein the dashed line represents the presence or absence of a double bond; J is C.dbd.O or CHOH; A is --(CH.sub.2).sub.6--, or cis --CH.sub.2CH.dbd.CH--(CH.sub.2).sub.3--, wherein 1 or 2 carbons may be substituted with S or O; B is CO.sub.2H, or CO.sub.2R, CONR.sub.2, CONHCH.sub.2CH.sub.2OH, CON(CH.sub.2CH.sub.2OH).sub.2, CH.sub.2OR, P(O)(OR).sub.2, CONRSO.sub.2R, SONR.sub.2, or ##STR00002## R is H, C.sub.1-6 alkyl; D is --(CH.sub.2).sub.n--, --X(CH.sub.2).sub.n, or --(CH.sub.2).sub.nX--, wherein n is from 0 to 3 and X is S or O; and E is an aromatic or heteroaromatic moiety having from 0 to 4 substituents, said substituents each comprising from 1 to 6 non-hydrogen atoms is disclosed herein. Methods, compositions, and medicaments related thereto, as well as experimental results showing prostaglandin EP4 selective agonist activity for certain compounds disclosed herein, are also disclosed.